Dolutegravir, and Lamivudine

Common Brands Actos
Drug Class
Controlled Substance Classification
Not a controlled medication
Generic Status
Lower-cost generic available
Prescription only
Robert Chad Hakim, PharmD, BCCCP
Robert Chad Hakim, PharmD, BCCCP
Read More
Medically reviewed by Robert Chad Hakim, PharmD, BCCCP last update on 20/12/2023


Dolutegravir, an integrase strand transfer inhibitor (INSTI), stands as a potent antiretroviral medication widely employed in the management of HIV-1 infection. Approved by regulatory authorities globally, Dolutegravir has revolutionized HIV therapy, demonstrating high efficacy and a favorable side effect profile.

Dolutegravir exerts its therapeutic effects by inhibiting the activity of the viral integrase enzyme. This crucial enzyme facilitates the integration of the viral genetic material into the host cell DNA, a necessary step for HIV replication. By interfering with this process, Dolutegravir disrupts the viral life cycle, leading to a reduction in viral load and a subsequent increase in CD4 cell counts.

Dolutegravir is commonly available in tablet form for oral administration. The recommended dosage is typically 50 mg once daily, with or without food. The ease of administration and a relatively low pill burden contribute to its adherence-friendly profile.



Prescription only

Pregnancy & Lactation